Silence Therapeutics to present positive data from 'SLN124'
Silence Therapeutics announced on Monday that it would present data showing the potential for ‘SLN124’ to address a range of hematological diseases by targeting the liver-expressed gene TMPRSS6.
The AIM-traded firm said the presentation would be made during two poster sessions at the European Hematology Association (EHA) virtual congress to be held from 9 June.
It said the presentations would include a preclinical safety assessment of SLN124, which would show data that was consistent with recent positive topline clinical data from the ‘GEMINI’ phase 1 study of SLN124 in healthy volunteers announced in May.
“SLN124 is being evaluated in the ongoing GEMINI II phase 1 study in patients with thalassemia and myelodysplastic syndrome,” the board said in its statement.
“A second poster will present encouraging preclinical evidence that using siRNA to target TMPRSS6 could be a viable therapeutic avenue for treatment of the rare blood disorder, polycythaemia vera (PV).”
At 0933 BST, shares in Silence Therapeutics were up 1.09% at 639.91p.